News Category
Scinai Immunotherapeutics has raised approximately $4 million through a private placement and warrant inducement transaction, providing capital to exp...
Nutriband Inc. (NASDAQ: NTRB) raised approximately $1.75 million through warrant exercises, funding the remaining clinical development and New Drug Ap...
Quantum BioPharma's agreement with Thermo Fisher's clinical research business moves its novel neuroprotective multiple sclerosis drug Lucid-MS into a ...
The CDSCO's authorization of Okogen's EMERALD Phase 1/2 study for Treyegen (OKG-0303) marks a significant step toward a much-needed dual-action treatm...
Helus Pharma Inc. has officially changed its legal name from Cybin Inc., effective October 1, 2026, after shareholder approval, marking its transition...
Apimeds Pharmaceuticals US subsidiary MindWave Innovations will provide blockchain infrastructure for AQUAE Holdings' new insured ALCI Credits platfor...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant that supports natural cartilage regeneration, offering a potential new ...
American Fusion's Texatron program has advanced to active testing with record-breaking confinement pressures, potentially accelerating the path to com...
The upcoming Moody Capital Solutions conference will spotlight emerging and under-covered companies, offering a structured format of presentations and...
SuzieQ Holdings Inc. will be featured at the Moody Capital Solutions 2026 conference, highlighting its role in building the measurement and sovereignt...
A new study confirms that treating certain emergency room patients while seated, rather than waiting for a bed, can significantly reduce wait times an...
Helus Pharma reported completion of enrollment in its pivotal Phase 3 APPROACH trial for HLP003 in major depressive disorder, with topline data expect...
Helus Pharma has appointed Michael Halstead as CEO, bringing extensive biopharmaceutical experience to lead the company through pivotal Phase 3 trials...
Ocumetics Technology Corp. completed the second tranche of its private placement, raising $2.5 million to fund its first-in-human clinical trials and ...
VERAXA Biotech AG shareholders approved proposals to enhance corporate governance and financing flexibility, supporting the company's long-term growth...
VERAXA Biotech AG and OmniAb have reached a key milestone in their collaboration, advancing VXA-222, a bispecific antibody-drug conjugate designed to ...
Gerresheimer has commenced operations at a new, sustainable plant in Zhenjiang Dagang, China, doubling its production capacity for glass primary packa...
Helus Pharma completed enrollment in its pivotal Phase 3 APPROACH trial for HLP003, a deuterated psilocin analogue for major depressive disorder, with...
Darwin AG has officially changed its name to Novogenia AG, aligning its corporate identity with its core operating brand to enhance market visibility ...
NanoViricides is progressing its oral gummies formulation of NV-387 toward a Phase II trial for the Bundibugyo ebolavirus outbreak in the DRC, where n...
Redwood AI Corp. has been included in the CSE25 Index, reflecting its growth and potentially increasing its appeal to institutional and retail investo...
Helus Pharma announced fiscal 2026 financial results and provided updates on its clinical pipeline, with its lead candidate HLP003 for major depressiv...
Quantum BioPharma Ltd. is highlighted in a BioMedWire editorial for its novel drug candidate Lucid-MS, which directly targets myelin repair in multipl...
The article highlights how advanced drug delivery systems, such as Oncotelic Therapeutics' Deciparticle platform, are gaining attention as a cost-effe...
Quantum BioPharma's Lucid-MS, a first-in-class neuroprotective drug candidate for multiple sclerosis that directly targets myelin sheath damage, prepa...
VERAXA Biotech announced new in vitro proof-of-concept data for its BiTAC-ADC platform, demonstrating tumor-restricted activation and dose-dependent k...
Redwood AI Corp. is highlighted as a company to watch for its AI-powered platforms that aim to speed up chemistry research and development in pharmace...
NanoViricides has received approval from the Democratic Republic of Congo's Pillar Committee to conduct a Phase II clinical trial of its oral antivira...
Helus Pharma announced that its Chief Medical Officer will participate in a fireside chat at the H.C. Wainwright Neuro Perspectives Conference, highli...
Onco-Innovations Limited has initiated process development and scale-up for its drug candidate ONC010, a key step toward regulatory readiness and firs...
Quantum BioPharma Ltd. announced the completion of Phase 1 clinical studies for LUCID-MS, a therapy targeting myelin repair in multiple sclerosis, and...
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference, providing updates on its OneRF platform for brain and pai...
GeoVax CEO David Dodd comments on recent pharmaceutical industry acquisitions, emphasizing the growing strategic importance of vaccine innovation, man...
Quantum BioPharma's co-founder discusses the potential of Lucid-MS for multiple sclerosis and the commercial success of unbuzzd, with an upcoming Phas...
Helus Pharma's participation in the Jefferies Global Healthcare Conference highlights its advancing pipeline of novel serotonergic agonists for mental...
TransCode Therapeutics has started a Phase 2a clinical trial of its lead candidate TTX-MC138 in colorectal cancer patients with minimal residual disea...
NanoViricides announces that its broad-spectrum antiviral NV-387 may be evaluated for treating the Bundibugyo Ebola outbreak, citing its host-targeted...
SureNano Science Ltd. is advancing GEP-44, a next-generation GLP-1 peptide for obesity and metabolic disorders, aiming to differentiate itself in the ...
Oncotelic Therapeutics' integration of 28 million scientific abstracts into its PDAOAI platform positions the small biotech as a contender in the AI-d...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn improves survival and reduces oxidative stress and liver copper in...
Lantern Pharma announced FDA clearance for protocol amendments to its Phase 2 HARMONIC trial, focusing on EGFR-mutant never-smoker lung cancer patient...
NanoViricides, Inc. emphasized the potential of its oral drug candidate NV-387 as a pandemic preparedness tool for Ebola and related viral threats, ci...
Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has reached the halfway enroll...
LIXTE Biotechnology announced continued advancement of its lead oncology candidate LB-100, including an expanded ovarian cancer trial, and growth at i...
Dogwood Therapeutics announced progress in its non-opioid pain treatment pipeline, including Phase 2b data for Halneuron® expected in fall 2026 and FD...
Innovations in bypassing the blood-brain barrier, such as Oncotelic's intranasal nose-to-brain delivery system, are opening new avenues for treating C...
Silo Pharma announced a strategic initiative to develop ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provis...
Three deaths linked to hantavirus on the MV Hondius cruise ship highlight the dangers of this rare infection and the importance of diagnostic developm...
